Vicebio launched by medicxi to advance the Molecular Clamp technology and develop next generation RSV vaccine

• Focused on delivering highly effective vaccines against life-threatening respiratory viral infections
• Exclusive commercial licence to technology platform developed at The University of Queensland
• Industry leader Dr Emmanuel Hanon appointed Chief Executive Officer


London, UK, 21 July 2022: Vicebio Ltd (“Vicebio”), a biopharmaceutical company founded by medicxi in 2019, today announces its launch to accelerate the development of novel vaccines against life-threatening respiratory viral infections using its novel Molecular Clamp technology platform. This technology has been developed by Prof Paul Young, Dr Daniel Watterson, Dr Keith Chappell and their groups at The University of Queensland (UQ), Brisbane, Australia and licensed to Vicebio by UniQuest, the commercialisation company of UQ. Medicxi has so far committed €18M to progress this technology into the clinic. Dr Emmanuel Hanon, the former Head of Vaccines R&D at GSK, has been appointed as Chief Executive Officer.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH